Invitation to Presentation of Immunovia´s Interim Report January - September 2020 on November 12, 2020
LUND, Sweden, Nov. 6, 2020 /PRNewswire/ -- Immunovia invites to a teleconference (in English) for investors, analysts and media on Thursday, November 12, 2020 at 16:30 CET. Immunovia will publish the company's interim report on November 12, 2020 at 16:00 CET.
Patrik Dahlen, CEO will present Immunovia and comment on the interim report for the period January - September 2020 followed by a Q&A session. Please call in a few minutes in advance.
To attend, please dial-in at one of the numbers below and provide the conference code Immunovia to the operator:
Conference Call
Sweden: +46 (0) 8 50520424
United States: +1 212 999 6659
France: +33 (0) 1 7037 7166
Denmark: +45 3272 9273
Germany: +49 (0) 30 3001 90612
Spain: +34 91 787 0777
Netherlands: +31 (0) 20 708 5073
Norway: +47 2 156 3318
Austria: +43 (0) 12530807
Switzerland: +41 (0) 22 592 7915
United Kingdom (Standard International Access): +44 (0) 20 3003 2666
Conference Code: (to provide to the operator) Immunovia
Immunovia Webcast: https://channel.royalcast.com/immunovia/#!/immunovia/20201112_1
For more information, please contact:
Julie Silber, Director of Investor Relations, Immunovia
Email: [email protected]
Tel: +46 7 93 486 277
There will be an MP3-file available at Immunovia's webpage under Investors/Financial Reports (http://immunovia.com/investors/financial-reports/) for those who want to listen to the telephone conference afterwards. The file will be available within two hours after the conference has ended.
About Immunovia
Immunovia AB is a diagnostic company that is developing and commercializing highly accurate blood tests for the early detection of cancer and autoimmune diseases based on Immunovia's proprietary test platform called IMMray™. Tests are based on antibody biomarker microarray analysis using advanced machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a unique "disease biomarker signature".
The company was founded in 2007, based on cancer studies and ground-breaking research in the Department of Immuntechnology at Lund University and CREATE Health Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical evaluation in some of the world's largest clinical studies for pancreatic cancer, PanFAM-1, PanSYM-1 and PanDIA-1 and is currently in the final validation phase. The company aims for a sales start at the end of Q1 2021 with subsequent commercial testing in Q2.
When validated, IMMray™ PanCan-d will be the first blood-based test for early diagnosis of pancreatic cancer on the market, with a potential to significantly improve patient survival and outcome.
Immunovia Dx Laboratories located in Marlborough, Massachusetts, USA and Lund, Sweden will provide laboratory testing services in two accredited reference laboratories.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
SOURCE Immunovia AB
Share this article